Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 11/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845660 | 0.93 | FFAR1 (0.54) | FFAR1PPARGMAPTPPARA | |
| SCHEMBL5403539 | 0.89 | FFAR1 (0.57) | FFAR1PPARGPPARA | |
| SCHEMBL4851773 | 0.88 | KDR (0.48) | FFAR1PPARGMAPTPPARARXFP1 | |
| SCHEMBL5413103 | 0.87 | KDR (0.55) | FFAR1PPARGPPARA | |
| SCHEMBL4850509 | 0.85 | FFAR1 (0.46) | FFAR1PPARGMAPTPPARAKMT2A | |
| SCHEMBL4850523 | 0.85 | MAPT (0.46) | FFAR1PPARGMAPTPPARASMN1; SMN2 | |
| SCHEMBL4852292 | 0.84 | FFAR1 (0.39) | FFAR1PPARGMAPTPPARARXFP1 | |
| SCHEMBL4853077 | 0.83 | FFAR1 (0.43) | FFAR1PPARGMAPTPPARARXFP1 | |
| SCHEMBL4853083 | 0.83 | FFAR1 (0.43) | FFAR1PPARGMAPTPPARARXFP1 | |
| SCHEMBL4848043 | 0.82 | MAPT (0.43) | FFAR1PPARGMAPTPPARARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | FFAR1 14/4885PPARG 433/4885MAPT 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.